Emerging Role of IGF-1 Deficiency in Cardiovascular Aging: Recent Advances.” J Gerontol A Biol Sci Med Sci (2012) 67A (6): 599-610.
Valimaki MJ et alEffects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 1999 Jun; 140(6):545-54
van Dam PS Somatropin therapy and cognitive function in adults with growth hormone deficiency: a critical review. Treat Endocrinol. 2006; 5(3):159-70
Van Der Lely et al. Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 2000 Nov; 143(5):585-592
Wang P et al. The role of endotoxin, TNF-alpha, and IL-6 in inducing the state of growth hormone insensitivity. World J Gastroenterol 2002 Jun; 8(3):531-6 AIM:
Wren AM et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion, Endocrinology 2000 Nov;141(11):4325-8
Yancy CW, Jessup M, Bozkurt B, Masoudi FA, et al; ACCF/AHA Task Force Members. “2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.” J Am Coll Cardiol. 2013 Jun 5.
DHEA
Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res. 2008; 31:69-74.
Baulieu E.E., Thomas G., Legrain S., Lahlou N., Roger M., Debuire B., Faucounau V., Girard L., Hervy M.P., Latour F., Leaud M.C., Mokrane A., Pitti-Ferrandi H., Trivalle C., de Lacharriere O., Nouveau S., Rakoto-Arison B., Souberbielle J.C., Raison J., Le Bouc Y., Raynaud A., Girerd X., Forette F. (2000). Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA, 97(8):4279–4284.
Baulieu E.E. (1996). Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metabo, 81:3147–3151.
Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519-1524.
Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation. 1995;91:1757-1760.
Chiu KM, Schmidt MJ, Havighurst TC, Shug AL, Daynes RA, Keller ET, Gravenstein S. Correlation of serum L-carnitine and dehydro-epiandrosterone sulphate levels with age and sex in healthy adults. Age Ageing. 1999;28:211-216.
Ciolino H, MacDonald C, Memon O, Dankwah M, Yeh GC. Dehydroepiandrosterone inhibits the expression of carcinogen-activating enzymes in vivo. Int J Cancer. 2003;105:321-325.
Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001;61:7449-7455.
de Heredia FP, Cerezo D, Zamora S, Garaulet M. Effect of dehydroepiandrosterone on protein and fat digestibility, body protein and muscular composition in high-fat-diet-fed old rats. Br J Nutr. 2007;97:464-470.
Ho HY, Cheng ML, Chiu HY, Weng SF, Chiu DT. Dehydroepiandrosterone induces growth arrest of hepatoma cells via alteration of mitochondrial gene expression and function. Int J Oncol. 2008;33:969-977.
Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res. 1995;55:3949-3953.
Kumar P, Taha A, Sharma D, Kale RK, Baquer NZ. Effect of dehydroepiandrosterone (DHEA) on monoamine oxidase activity, lipid peroxidation and lipofuscin accumulation in aging rat brain regions. Biogerontology. 2008;9:235-246. Erratum in: Biogerontology. 2008;9:283-284.
Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78:1360-1367. Erratum in: J Clin Endocrinol Metab 1995;80:2799.
Page JH, Ma J, Rexrode KM, Rifai N, Manson JE, Hankinson SE. Plasma dehydroepiandrosterone and risk of myocardial infarction in women. Clin Chem. 2008;54:1190-1196.
Rabijewski M, Zgliczyński W. Positive effects of DHEA therapy on insulin resistance and lipids in men with angiographically verified coronary heart disease--preliminary study]. Endokrynol Pol. 2005 Nov-Dec;56(6):904-10.
Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, McCormick DL. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 1999;59:3084-3089.
Reiter WJ, Pycha A, Schatzl G, Pokorny A, Gruber DM, Huber JC, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999;53:590-594; discussion 594-5.
Stuckelberger A. (2008). Anti-Ageing Medicine : Myths and Chances. ETH Verlag, Zurich, Switzerland.
Yang S, Fu Z, Wang F, Cao Y, Han R. Anti-mutagenicity activity of dehydroepiandrosterone. Zhonghua Zhong Liu Za Zhi. 2002;24:137-140. Chinese.
Testosterone
Agarwal PK et al. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 Feb; 173(2):533-6.
Alexander GM, Swerdloff RS, Wang C, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Hormones and Behavior 1998; 33(2):85-94.
Algarte-Genin M et al. Prevention of Prostate Cancer by Androgens: Experimental paradox or clinical reality? European Urology 46 (Sept 2004) 285-295
Araujo Ab et al Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clinical Endocrinol Metabolism 2004 Dec; 89(12):5920-6.
Arnlov J et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1; 145(3):176-84
Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, Uzun O, Bolu E, Saglam K. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J. 2012 Aug 31.
Barrett-Connor E et al. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999 Oct; 84(10):3681-5
Basaria et al. November 2001 Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases. The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 11 5108-5117
Bhasin S et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun; 91(6):1995-2010.
Bhasin S. et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997 Feb; 82(2):407-13.
Bhasin S. The dose-dependent effects of testosterone on sexual function and on muscle mass and function. Mayo Clin Proc. 2000 Jan; 75 Suppl: S70-5
Boyanov
